Human/Mouse/Rat Phospho-MEK1 (S218/S222)/MEK2 (S222/S226) Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB8407
Recombinant Monoclonal Antibody.
Conjugate
Catalog #
Key Product Details
Validated by
Biological Validation
Species Reactivity
Human, Mouse, Rat
Applications
Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Rabbit IgG Clone # 1020E
Product Specifications
Immunogen
Phosphopeptide containing the human, mouse, and rat MEK1 S218/S222 site
Specificity
Detects human, mouse, and rat MEK1 and MEK2 dually phosphorylated at S218/S222 and S222/S226, respectively.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for Human/Mouse/Rat Phospho-MEK1 (S218/S222)/MEK2 (S222/S226) Antibody
Detection of Human Phospho-MEK1 (S218/S222)/ MEK2 (S222/S226) by Western Blot.
Western blot shows lysates of Jurkat human acute T cell leukemia cell line and HeLa human cervical epithelial carcinoma cell line untreated (-) or treated (+) with 200 nM PMA or PMA and Ionomycin for 20 minutes. PVDF membrane was probed with 0.5 µg/mL of Rabbit Anti-Human/Mouse/Rat Phospho-MEK1 (S218/S222)/ MEK2 (S222/S226) Monoclonal Antibody (Catalog # MAB8407) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-MEK1 (S218/S222)/ MEK2 (S222/S226) at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.Applications for Human/Mouse/Rat Phospho-MEK1 (S218/S222)/MEK2 (S222/S226) Antibody
Application
Recommended Usage
Western Blot
0.5 µg/mL
Sample: Jurkat human acute T cell leukemia cell line and HeLa human cervical epithelial carcinoma cell line treated with PMA or PMA and Ionomycin
Sample: Jurkat human acute T cell leukemia cell line and HeLa human cervical epithelial carcinoma cell line treated with PMA or PMA and Ionomycin
Formulation, Preparation, and Storage
Purification
Protein A or G purified from cell culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: MEK1/MEK2
MEK1 and MEK2, also known as MAP2K1 and MAP2K2, are activated in response to mitogenic stimuli. Activation occurs through dual phosphorylation at S218/S222 of MEK1 and S222/S226 of MEK2 by several upstream MAP3Ks, including the Raf kinases. Both MEK1 and MEK2 are dual-specificity protein kinases, phosphorylating and activating ERK1 and ERK2 at Thr and Tyr positions.
Long Name
Mitogen-activated Protein Kinase Kinase 1
Alternate Names
CFC3, CFC4, dual specificity mitogen-activated protein kinase kinase 1, dual specificity mitogen-activated protein kinase kinase 2, ERK activator kinase 1, ERK activator kinase 2, MAP kinase kinase 2, MAPK/ERK kinase 1, MAPK/ERK kinase 2, MAPKK 1, MAPKK1, MAPKK2, MEK 1, MEK1, MEK2, MEL, mitogen-activated protein kinase kinase 2, p45, MKK1, MKK2, PRKMK1, PRKMK2, protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1)
Additional MEK1/MEK2 Products
Product Documents for Human/Mouse/Rat Phospho-MEK1 (S218/S222)/MEK2 (S222/S226) Antibody
Product Specific Notices for Human/Mouse/Rat Phospho-MEK1 (S218/S222)/MEK2 (S222/S226) Antibody
* Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to SDS for additional information and handling instructions.
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...